Envestnet Asset Management Inc. Buys 12,545 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Envestnet Asset Management Inc. raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 1.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 736,326 shares of the company's stock after acquiring an additional 12,545 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.11% of Genmab A/S worth $14,417,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S during the fourth quarter worth about $2,463,000. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock worth $656,000 after buying an additional 31,343 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Genmab A/S by 18.8% during the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company's stock worth $12,509,000 after buying an additional 94,858 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Genmab A/S by 55.2% during the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock worth $1,205,000 after buying an additional 20,525 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in shares of Genmab A/S by 3.3% during the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after buying an additional 6,288 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Wall Street Zen downgraded shares of Genmab A/S from a "buy" rating to a "hold" rating in a research note on Sunday. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded up $0.11 during mid-day trading on Tuesday, reaching $21.80. The company had a trading volume of 834,789 shares, compared to its average volume of 1,247,127. The stock has a fifty day moving average of $21.18 and a two-hundred day moving average of $20.78. The company has a market capitalization of $13.99 billion, a price-to-earnings ratio of 12.39, a PEG ratio of 6.59 and a beta of 0.94. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.